Plain-English translation of NCT05824975 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which works by boosting your immune system to fight cancer cells. Researchers want to find the right dose and see how well it works when given by itself or combined with other cancer treatments like or trastuzumab deruxtecan. The medication is designed to activate your body's natural cancer-fighting cells while reducing immune cells that protect tumors.
Current cancer treatments don't work well enough for all patients, especially those whose cancers have become resistant to other immunotherapies. This trial exists to test whether this new medication, which targets cancer cells in a different way, could help patients with advanced cancers that haven't responded to standard treatments.
You likely qualify if…
You likely don't qualify if…
You will receive either as an injection under the skin or through an IV infusion, either alone or combined with another cancer drug, depending on which study arm you're enrolled in. The trial has multiple phases where the dose may be adjusted to find the safest and most effective level. You will have regular visits for blood tests, scans, and physical exams to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States